Schorr · Journal of drugs in dermatology : JDD 2012 · randomized split-face trial · n=?

Adjunctive use of a facial moisturizer SPF 30 containing ceramide precursor improves tolerability of topical tretinoin 0.05%: a randomized, investigator-blinded, split-face study.

Cited 14 times in the scientific literature.

Level 2 - randomized trial

Randomized, investigator-blinded, split-face controlled trial

PubMed 23135655 · record verified 2026-08-29

What was done

A randomized, investigator- and evaluator-blinded, split-face study was conducted in subjects with healthy skin. All participants applied topical tretinoin cream 0.05% once daily to the entire face, alongside Cetaphil Dermacontrol Moisturizer SPF 30 (CDM, containing a ceramide precursor) applied once daily to one randomized side of the face. Tolerability, preference, and skin hydration were assessed weekly, and a cosmetic acceptability questionnaire was administered at the end of the study.

What was found

Approximately 83% to 86% of subjects experienced skin irritation on both sides of the face. However, irritation was predominantly mild on the side treated with CDM plus tretinoin. Subject tolerability preferences favored the CDM-treated side. Specific numerical scores, hydration measures, and statistical significance values were not reported in the abstract.

Why it matters

Adjunctive application of a ceramide-containing moisturizer with SPF 30 helps mitigate the local irritation commonly caused by topical tretinoin, potentially improving patient compliance with retinoid therapy.

Limits

The abstract omits key methodological details, including the sample size, duration of the study, and specific quantitative data for hydration and tolerability endpoints. The study was conducted in subjects with healthy skin rather than clinical acne or photoaging populations, and evaluator blinding cannot fully rule out participant bias in self-reported preference and tolerability outcomes.

Cited by